Evidence map›Paper›PMID 39211617›Full record

ArticleJACS Au2024

Eric Brandhorst, Liang Xu, Maxime Klimezak, Bastien Goegan, Huixiao Hong, Hans-Peter Hammes, Alexandre Specht, Sidney Cambridge

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in JACS Au, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Eric BrandhorstFifth Medical Department, Medical Faculty Mannheim, University of Heidelberg, 68167 Mannheim, Germany.
Liang XuDivision of Bioinformatics and Biostatistics, National Center for Toxicological Research, U.S. Food and Drug Administration, 3900 NCTR Road, Jefferson, Arkansas 72079, United States.ORCID https://orcid.org/0000-0002-6556-7521
Maxime KlimezakLaboratoire de Chémo-Biologie Synthétique et Thérapeutique, Equipe Nanoparticule Intelligentes, Université de Strasbourg, CNRS, CBST UMR 7199, F-67000 Strasbourg, France.
Bastien GoeganLaboratoire de Chémo-Biologie Synthétique et Thérapeutique, Equipe Nanoparticule Intelligentes, Université de Strasbourg, CNRS, CBST UMR 7199, F-67000 Strasbourg, France.
Huixiao HongDivision of Bioinformatics and Biostatistics, National Center for Toxicological Research, U.S. Food and Drug Administration, 3900 NCTR Road, Jefferson, Arkansas 72079, United States.ORCID https://orcid.org/0000-0001-8087-3968
Hans-Peter HammesFifth Medical Department, Medical Faculty Mannheim, University of Heidelberg, 68167 Mannheim, Germany.
Alexandre SpechtLaboratoire de Chémo-Biologie Synthétique et Thérapeutique, Equipe Nanoparticule Intelligentes, Université de Strasbourg, CNRS, CBST UMR 7199, F-67000 Strasbourg, France.ORCID https://orcid.org/0000-0001-5056-5278
Sidney CambridgeDr. Senckenberg Anatomy, Anatomy II, Goethe-University Frankfurt, 60590 Frankfurt am Main, Germany.ORCID https://orcid.org/0000-0002-6438-4037

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The retina is prone to developing pathological neovascularization, a leading cause of blindness in humans. Because excess neovascularization does not affect the entire retina, global inhibition treatment of angiogenesis critically interferes with healthy, unaffected retinal tissue. We therefore established an

Identifiers

PMID39211617
PMCPMC11350597

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.